Financière Boscary
VC Fund
Financière Boscary is a financial firm that offers investment services with a focus on small and mid-sized enterprises.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Financière Boscary invests in
Stages Financière Boscary invests in
Countries Financière Boscary invests in
Investment Focus
Industry
- Electronics 2 (67%)
- Energy 1 (33%)
- Mobile 1 (33%)
- Medical 1 (33%)
- Biopharma 1 (33%)
Stage
- Funding Round 2 (67%)
- Series A 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
SunPartner
|
SunPartner develops and commercializes innovative technologies adapted to communication, energy, transportation, and building needs. It offers Wysips Crystal, an ultra-thin and transparent photovoltaic material with an optical system designed for emissive screens for smartphones and smartwatches; Wysips Graphics masks solar cells for connecteddevices; Wysips Reflect that can be integrated into any kind of reflective screen; Wysips Cameleon for signs and billboard; and Light-Fidelity or Visible Light Communication, a communication technology that transmits data over visible light waves and has applications in location-based services, electromagnetic sensitive places, shopping 2.0, and smartCities.SunPartner is a France-based company that was founded in 2008. | $2.1M / Jul 26, 2012 | |
Andelia
|
Andelia is an organization which manufactures touch kiosks. They design and develop interactive information point | $671K / May 14, 2012 | |
Pharnext
|
Pharnext is an advanced clinical-stage biopharmaceutical company founded in April 2007 by renowned scientists and entrepreneurs including Professor Daniel Cohen and collaborators, pioneers in modern genomics. The company develops new therapeutics for neurodegenerative diseases - orphan and common – where there are currently no cures and existingtherapies available.Pharnext is the pioneer of a new paradigm for the discovery of medicinal drugs: PLEOTHERAPY™. The R&D approach protected by Pharnext systemizes new uses of approved drugs. It is based on network pharmacology utilizing complex and extensive genomic data to identify the thousands of molecules possibly involved in a disease. From this disease molecular network, Pharnext deduces synergistic combinations of drugs already approved but for unrelated indications. These novel therapeutics called PLEODRUG™ are then developed at new optimal doses and under new formulations. They offer several key advantages: efficacy, safety, and intellectual property including several composition of matter patents already granted.The proof of concept of the PLEOTHERAPY approach was obtained with PLEODRUG PXT3003 in Charcot-Marie-Tooth disease type 1A (CMT1A) through positive and consistent Phase 2 and Phase 3 results.PLEODRUG PXT864 generated encouraging Phase 2 data in Alzheimer’s disease. They also plan to develop the same agent in other orphan and common neurodegenerative diseases such as Parkinson’s disease and amyotrophic lateral sclerosis (ALS). | $5.8M / Series A / Jun 14, 2010 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Financière Boscary invest in?
Financière Boscary invests primarily in Electronics, Energy and Mobile startups, most often at Funding Round and Series A stage. Most of the 3 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Financière Boscary last invest?
The most recent investment recorded for Financière Boscary closed in Jul 2012. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
